Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 97
Phase 3 extension trial in adults and phase 2 trial in
children for once-weekly somapacitan to conclude in 2018
Somapacitan IGF-1 levels similar to daily
Norditropin in REAL 1 phase 3 AGHD trial
Cumulative
frequency
100%
80%
60%
40%
20%
Baseline
Placebo
NorditropinⓇ
somapacitan
Phase 3a AGHD trial succesfully completed,
phase 2 GHD read-out expected in 2018
REAL 1: Phase 3a,
naïve AGHD
Objective: Efficacy
(truncal fat %)/safety __
REAL 3: Phase 2, GHD
Objective: Dose finding
(height velocity)/safety
Completed trial
Ongoing trial
¡Extension trial>
Trial in planning
REAL 4: Phase 3, GHD
Objective: Efficacy
(height velocity)/safety
REAL 5: Phase 3, SGA
Objective: Efficacy
(height velocity)/safety
0%
-3 -2 -1
0
1
2
3
2016
2017
2018
2019
IGF-1 standard deviation score
IGF-1: Insulin-like growth factor 1; AGHD: Adult growth hormone deficiency
Source: Novo Nordisk data on file; REAL 1, NN8640-4054
changing
diabetes®
Note: Filing for first indication (AGHD) expected in 2018
GHD: Growth hormone deficiency; SGA: Small for gestational age
2020
2021
novo nordiskView entire presentation